The World Anti-Doping Agency (WADA) announced on Monday that it will not appeal to the Court of Arbitration for Sport (CAS) in the case of Iga Świątek after the former world number one tested positive for the prohibited substance trimetazidine (TMZ).
The five-time Grand Slam champion agreed to a one-month suspension in November after testing positive for TMZ in an out-of-competition sample in August, which was due to contamination of her medication with melatonin.
READ | Australian Open 2025: Świątek crushes Lys’ lucky loss and reaches the quarterfinals
Swiatek stated that she was taking it for jet lag and sleep problems, but was not given a long-term ban after the International Tennis Integrity Agency (ITIA) found that she had not committed significant fault or negligence on her part.
“WADA has completed a full review of the case file related to the ITIA decision that it received on November 29,” WADA said in a statement.
“WADA scientific experts have confirmed that the specific melatonin contamination scenario presented by the athlete and accepted by ITIA is credible and that there is no scientific basis to challenge it at CAS.”
Men’s world number one Jannik Sinner continues to be under investigation after testing positive for the anabolic drug clostebol. The Italian was also cleared of the charges, but WADA appealed to CAS, whose hearing began on April 16.
